CTI Clinical Trial & Consulting Services Announces Formation of Swedish Canadian Subsidiaries and Office
[Cincinnati, OH ~ November 5, 2015]
CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization announces that it has opened an office in Stockholm, Sweden. The office is opened through the wholly-owned subsidiary, Clinical Trial and Consulting Services Sweden AB. The company has opened more than a dozen offices over the past few years, with additional international expansion planned for 2016.
“We have been conducting studies in Sweden with our own staff for many years, and felt that our international growth necessitated a physical presence in the country to better serve our pharmaceutical and biotechnology clients,” states Patrick Earley, Vice President, International.
Additionally, the company has started a wholly-owned subsidiary in Canada, CTI Clinical Trial & Consulting Services Canada ULC, with plans for an office in the future. According to Earley, “This new subsidiary shows CTI’s commitment to the high quality of research in Canadian hospitals and universities, as well as enables our sponsors to take advantage of research tax incentives that are provided by the government.”
CTI has been working for seventeen years in the drug development industry across North America, Europe, South America, Pac-Asia, and Africa, specializing in clinical research programs involving critically ill patient populations, and has more than 25 offices worldwide to serve nearly 100 pharmaceutical, biotechnology, and medical device clients.
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
